Submission Guidelines

Abstracts which do not abide by the submission guidelines will not be sent for review and/or will not be eligible for presentation at the SIU Regional Meeting for Residents in Urology.

1. Basic Information

i. Important Dates

*All deadlines are 11:59 PM China Time (CST UTC+8) and are subject to change.

2. Rules for Authors

i. Prior Publication of Material

The SIU Regional Meeting for Residents in Urology is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before November 20, 2026. If the work has been presented at another meeting, the author must disclose when and where it was presented on the submission form, so that the Abstract Review Committee can make its decision based on all available details.

ii. Objectivity

The SIU is committed to offering participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the SIU urge all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.

iii. Registration

Presenting Authors must register before July 1, 2026. They will receive detailed information regarding registration and hotel arrangements. Additional information concerning visas can be consulted on the official web page of the Chinese Visa Application Service Center at https://www.visaforchina.cn/MTL3_FR/qianzhengyewu.

iv. Failure to Present

Inability to attend in-person will result in withdrawal of your abstract(s) for the SIU Regional Meeting for Residents in Urology.

v. Abstract Revisions

Abstracts may not be revised or resubmitted after the deadline of July 1, 2026. Submissions via email at any time will also not be accepted.

vi. Abstract Withdrawal

Please submit abstract withdrawal requests in writing via email to siucua@163.com by July 1, 2026, with your submission ID number(s).

vii. Change of Presenting Author

Please submit requests in writing via email to siucua@163.com by July 1, 2026, with your submission ID number(s). After this date, changes may not be reflected online and on any printed materials.

3. Rules for Presentation

i. Abstract Acceptance

Each abstract will be blinded and scored by the assigned reviewers. Abstracts will be accepted based on scientific merit. The Scientific Committee reserves the right to assign final presentation categories and alter topics/subtopics in the best interest of the programme.

ii. Publication and Copyright

All accepted abstracts will be published online as open access in the Société Internationale d’Urologie Journal (SIUJ) and online as an SIU ePoster. Publication of abstracts and ePosters implies transfer of copyright of the article to the Publisher. This will ensure the widest possible protection and dissemination of information under copyright laws. Should the author wish to reuse the submission at later events/publications, permission should be requested for publication with the following statement: "This abstract was presented at the 2026 SIU Regional Meeting for Residents in Urology, held in Conjunction with the 33rd Annual Meeting of the Chinese Urological Association (CUA 2026). All rights reserved. Reused with permission." By submitting an abstract, the submitter (and all identified authors) agrees with the conditions specified in the guidelines.

iii. Presentation Types

Presentation categories are as follows:

4. Preparation of Abstracts

i. Language

Abstracts must be written and presented in English. Careful typing and proofreading are essential. If accepted, the abstract will be published as submitted. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English will be glaringly apparent in the published abstract. Once the abstract is submitted, changes, corrections or rewording will not be possible. Presenters are requested to devote the necessary attention to language to avoid deviations from the use of good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision.

ii. Word Count

Abstracts must not exceed 350 words.

iii. Images, Tables and Graphs

Images, tables and graphs will not be accepted during the initial submission stage. Should your abstract be accepted, these elements can be added to your ePoster.

iv. Topic Area

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate topic as indicated on the submission form.

v. Learning Objectives

3–4 Educational Objectives must be submitted for each abstract.

vi. Abstract Title

Your abstract must have a short, specific title (no abbreviations) that indicates the nature of the investigation.
       Please use title case. Example: "Complications in Laparoscopic Transperitoneal Partial Nephrectomy."
       Consult Sample Abstract for additional information.

vii. Sections

Abstracts must include the following four distinct sections:

• Introduction and Objectives

• Materials and Methods

• Results

• Conclusion

viii. Drug Names

Use generic drug names.

ix. Abbreviations

Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase.

x. Acknowledgments

Do not include references, credits or grant support.

xi. Author Names and Affiliations

Author names and affiliations should not be present in the abstract title and abstract content as the abstract must be blinded for review.
       List of Authors: Do not include the authors list directly with your abstract. Only submit this information on the online form. There is only one presenting author permitted per submission. All Presenting Authors must complete, sign and submit a Conflict of interest disclosure form.
       Spelling: If an author's name appears on more than one abstract, it must be identical on each abstract to ensure proper indexing.

xii. Human Experimentation

Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the investigation should have been conducted in accordance with the principles of the World Medical Association’s Helsinki Declaration. The Scientific Committee may inquire further into ethical aspects when evaluating the abstract(s).

xiii. Abstract Data

Abstracts that describe single clinical cases, or investigations of compounds that involve inadequate numbers of study subjects or abstracts that lack quantitative data will not be accepted.
       Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
       Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified. Statements such as "results will be discussed" will automatically disqualify the abstract. Reviewers may require specific data on which to base their evaluation

xiv. Sample Abstract